Brought to you by 
Esperion sold by Pfizer; closes $55.8mm Series A round
03 May 2013
Executive Summary
After acquiring Esperion Therapeutics (cardiovascular and metabolic compounds) in 2003 for $1.25bn, Pfizer has now decided to spin off the company to a syndicate of investors. Esperion has simultaneously closed a tranched $22.75mm Series A venture round co-led by new investors Aisling Capital and Domain Associates, and returning backer Alta Partners, all of which contribute one member to the company's board. Arboretum Ventures also participated.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com